Toutes les études
Actif, mais pas en recrutementPHASE3INTERVENTIONNEL

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

This study is investigating a medication combination coded as ELX/TEZ/IVA for people with cystic fibrosis (CF). This treatment is for individuals who have CF but do not have the most common genetic change, called F508del, which affects the CFTR gene. The main aim is to see how safe the medication is and how well it helps people feel better and live healthier lives over a long period. Researchers will also look at how the medicine works in the body. This is a follow-on study for people who have already taken part in a previous trial, meaning they have some experience with these medicines. It’s part of a bigger effort to find effective treatments for all people with CF.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE3
Sponsor
Vertex Pharmaceuticals Incorporated
Objectif d'inscription
297
Démarrer
23 nov. 2022
Achèvement estimé
06 Apr 2027

De quoi parle cette étude ?

Cystic fibrosis (CF) is a condition that mainly affects the lungs and digestive system. It's caused by faulty genes. For many years, scientists have been working on new medicines that can fix some of these genetic problems, making a big difference for people with CF.

This particular study is focusing on a specific new treatment known as ELX/TEZ/IVA. What's special about this study is that it's for people with CF who don't have the most common genetic fault, called F508del. While some excellent treatments already exist for those with F508del, finding effective options for others is really important. This research aims to see if ELX/TEZ/IVA can help improve the health and well-being of these individuals.

The study will carefully follow volunteers over a long time to understand if the treatment is safe to use and if it effectively helps manage their CF symptoms. Researchers will also learn more about how the medicine works in the body. The goal is to provide more evidence that this treatment could be a safe and useful option for a wider group of people living with cystic fibrosis.

Points clés

  • This study is for people with CF who do not have the F508del gene change.
  • It evaluates the long-term safety and effectiveness of ELX/TEZ/IVA (and IVA).
  • Only people who completed a previous study with these medicines can join.
  • The study aims to expand treatment options for more people with CF.
  • Participation involves ongoing medication and regular health checks.

Qui peut être éligible ?

This study is for adults and children aged 6 years and older who have cystic fibrosis. To join, you would have already taken part in a previous study involving these same medicines (ELX/TEZ/IVA or IVA alone). This means you would have completed the treatment part of that earlier study, even if you had some short breaks from the medicine.

However, you won't be able to join if you had any bad reactions or couldn't tolerate the study medicine in the previous trial. The research team will also check for other specific health details to make sure the study is a safe and good fit for you.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. I am 6 years old or older.
  2. I have cystic fibrosis (CF).
  3. I do not have the F508del gene change in my CF diagnosis.
  4. I previously took part in another study with ELX/TEZ/IVA or IVA and completed the treatment part of it.
  5. I did not have any serious problems with the study medicines in that previous trial.
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you will continue to take the study medication (ELX/TEZ/IVA or IVA) as prescribed. You will have regular visits to the clinic, where the study team will carry out various health checks. These checks might include blood tests, lung function tests, and discussions about how you are feeling and any side effects you might be experiencing. The study is designed to follow participants over a long period, but the total duration for you would depend on how long you were in the previous study and the specific schedule set by the researchers. You’ll be carefully monitored throughout your participation.

Risques et avantages potentiels

Taking part in this study could offer potential benefits, such as continuing to receive an experimental treatment that may improve your cystic fibrosis symptoms and overall health. You would also contribute valuable information that could help others living with CF. However, like all medicines, ELX/TEZ/IVA and IVA can have side effects, and some people might not tolerate the treatment well. The study team will explain all known potential risks before you decide to join. Remember, you can choose to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (81)

  • Medizinische Universität Innsbruck - Heilstättenschule Universitätsklinik
    Code postal vérifié
    Innsbruck, Austria
  • CUB Hôpital Erasme
    Code postal vérifié
    Bruxelles, Belgique
  • UZ Brussel - Campus Jette
    Code postal vérifié
    Bruxelles, Belgique
  • Universitair Ziekenhuis Antwerpen (UZA) - Antwerp University Hospital
    Code postal vérifié
    Edegem, Belgium
  • Universitair Ziekenhuis Gent
    Code postal vérifié
    Gand, Belgique
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Code postal vérifié
    Leuven, Belgium
  • Universite Catholique de Louvain - Pulmonology
    Code postal vérifié
    Woluwe-Saint-Lambert, Belgium
  • Stollery Children's Hospital
    Code postal vérifié
    Edmonton, Canada
  • Le Centre de recherche du CHUM (CRCHUM)
    Code postal vérifié
    Montréal, Canada
  • McGill University Health Centre, Glen Site, Montreal Children's Hospital
    Code postal vérifié
    Montréal, Canada
  • Hospital for Sick Children - Pulmonology
    Code postal vérifié
    Toronto, Canada
  • British Columbia Children's Hospital
    Code postal vérifié
    Vancouver, Canada

Questions fréquentes

What is cystic fibrosis?

Cystic fibrosis (CF) is a genetic condition that mainly affects the lungs and digestive system, making mucus thick and sticky.

What does F508del mean?

F508del is the most common gene change that causes cystic fibrosis. This study is for people who don't have this specific change.

What medicines are being studied?

The study medicines are called ELX/TEZ/IVA (a combination) and IVA alone. They are designed to help the faulty protein in CF work better.

Devrai-je payer pour participer à l'étude ?

No, you will not have to pay for the study medication or any study-related tests and appointments.

Can I stop taking part if I change my mind?

Yes, you are free to withdraw from the study at any time without giving a reason, and it will not affect your future medical care.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.